# Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)

> **NCT00406393** · PHASE3 · COMPLETED · sponsor: **Medical College of Wisconsin** · enrollment: 304 (actual)

## Conditions studied

- Leukemia, Myelocytic, Acute
- Leukemia, Lymphocytic, Acute
- Leukemia, Myeloid, Chronic
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Tacrolimus
- **DRUG:** Methotrexate
- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT00406393
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2012-10
- **Final completion:** 2015-10
- **Target enrollment:** 304 (ACTUAL)
- **Last updated:** 2023-01-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00406393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00406393, "Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00406393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*